These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18941257)

  • 1. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions.
    Baudino L; Shinohara Y; Nimmerjahn F; Furukawa J; Nakata M; Martínez-Soria E; Petry F; Ravetch JV; Nishimura S; Izui S
    J Immunol; 2008 Nov; 181(9):6664-9. PubMed ID: 18941257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions.
    Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S
    J Immunol; 2008 Sep; 181(6):4107-12. PubMed ID: 18768867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of galactosylation enhances the pathogenic activity of IgG1 but Not IgG2a anti-erythrocyte autoantibodies.
    Ito K; Furukawa J; Yamada K; Tran NL; Shinohara Y; Izui S
    J Immunol; 2014 Jan; 192(2):581-8. PubMed ID: 24337750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.
    Azeredo da Silveira S; Kikuchi S; Fossati-Jimack L; Moll T; Saito T; Verbeek JS; Botto M; Walport MJ; Carroll M; Izui S
    J Exp Med; 2002 Mar; 195(6):665-72. PubMed ID: 11901193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia.
    Fossati-Jimack L; Reininger L; Chicheportiche Y; Clynes R; Ravetch JV; Honjo T; Izui S
    J Exp Med; 1999 Dec; 190(11):1689-96. PubMed ID: 10587359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.
    Fossati-Jimack L; Ioan-Facsinay A; Reininger L; Chicheportiche Y; Watanabe N; Saito T; Hofhuis FM; Gessner JE; Schiller C; Schmidt RE; Honjo T; Verbeek JS; Izui S
    J Exp Med; 2000 Apr; 191(8):1293-302. PubMed ID: 10770797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.
    Giorgini A; Brown HJ; Lock HR; Nimmerjahn F; Ravetch JV; Verbeek JS; Sacks SH; Robson MG
    J Immunol; 2008 Dec; 181(12):8745-52. PubMed ID: 19050295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.
    Baudino L; Nimmerjahn F; Azeredo da Silveira S; Martinez-Soria E; Saito T; Carroll M; Ravetch JV; Verbeek JS; Izui S
    J Immunol; 2008 Feb; 180(3):1948-53. PubMed ID: 18209093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
    Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
    J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
    Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
    J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.
    Ding JW; Zhou T; Zeng H; Ma L; Verbeek JS; Yin D; Shen J; Chong AS
    J Immunol; 2008 Jan; 180(1):261-8. PubMed ID: 18097027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells.
    Lobo PI; Patel HC
    Immunol Cell Biol; 1997 Jun; 75(3):267-74. PubMed ID: 9243292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
    Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
    Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site of binding of IgG2b and IgG2a by mouse macrophage Fc receptors by using cyanogen bromide fragments.
    Diamond B; Boccumini L; Birshtein BK
    J Immunol; 1985 Feb; 134(2):1080-3. PubMed ID: 3155534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
    Isaacs JD; Greenwood J; Waldmann H
    J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FcRs in animal model of autoimmune bullous pemphigoid.
    Zhao M; Trimbeger ME; Li N; Diaz LA; Shapiro SD; Liu Z
    J Immunol; 2006 Sep; 177(5):3398-405. PubMed ID: 16920981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
    Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
    Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.
    Leatherbarrow RJ; Rademacher TW; Dwek RA; Woof JM; Clark A; Burton DR; Richardson N; Feinstein A
    Mol Immunol; 1985 Apr; 22(4):407-15. PubMed ID: 4033665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.